Skip to Main Content

Author Details

Stephen R Plymate
University of Washington
1973
242
72
PMIDPaper TitleJournal TitlePublished Year
37065756ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.Front Endocrinol (Lausanne)2023
37652207Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.Lab Invest2023
37577653Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.bioRxiv2023
37352376Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.Cancer Res2023
35243412Starving lethal prostate cancer by targeting heat shock proteins and glycolytic enzymes.Cell Rep Med2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
36358940Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer.Biomolecules2022
33384381Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer.J Biol Chem2021
33516656AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.Cancer Treat Res Commun2021
33822745JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.Cancer Res2021
33658518Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.Nat Commun2021
34128479Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
33998604Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.J Clin Invest2021
31615710Clinical Acumen Versus Androgen Receptor Variant 7 Circulating Tumor Cells in Decision-Making for Men with Advanced Prostate Cancer.Eur Urol2020
35582223Intracrine androgen biosynthesis and drug resistance.Cancer Drug Resist2020
31932493Diverse <i>AR</i> Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer.Clin Cancer Res2020
32054790Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.Mol Cancer Ther2020
33163409Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer.Front Oncol2020
30334814Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.J Clin Invest2019
31503550Molecular determinants of response to high-dose androgen therapy in prostate cancer.JCI Insight2019
31575714Clinical Significance of AR-V567es in Prostate Cancer-Letter.Clin Cancer Res2019
31366581The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.Sci Transl Med2019
31036442Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
31002955Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).Contemp Clin Trials2019
30578319Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.Proc Natl Acad Sci U S A2019
30591516AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?Clin Cancer Res2019
28866255Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.Eur Urol2018
30135575Alternative splicing in prostate cancer.Nat Rev Clin Oncol2018
29856824A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.PLoS One2018
29955776Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.JAMA Oncol2018
30110398Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.PLoS One2018
29555663Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).Clin Cancer Res2018
29417861The potential of AR-V7 as a therapeutic target.Expert Opin Ther Targets2018
29358171Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.Cancer Res2018
29764892Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.BMJ Open2018
29258679Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.Eur Urol2018
27494249Response: letter to the editor.Expert Opin Ther Targets2017
28473532Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer.Cancer Res2017
28151719Neoadjuvant Enzalutamide Prior to Prostatectomy.Clin Cancer Res2017
29210989Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.Cancers (Basel)2017
28808043Allosteric alterations in the androgen receptor and activity in prostate cancer.Endocr Relat Cancer2017
27694897Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.Oncogene2017
26792867BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.Mol Cancer Res2016
26318705UDP-glucuronosyltransferase Enzymes in Prostate Cancer Progression: Is Only Androgen Catabolism Involved?Eur Urol2016
27897170Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer.Nat Commun2016
27197266Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Cancer Res2016
27117751Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Eur Urol2016
27261766AR-V7 Protein in Circulating Tumor Cells-The Decider for Therapy?JAMA Oncol2016
27140928Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Clin Cancer Res2016
26797685Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression.Horm Cancer2016
  • 1 - 50 of 242

Recommended Authors

Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 32
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2000
Number of shared co-authors 57
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 33
Renea A Taylor
Peter MacCallum Cancer Centre
Career Start Year 1999
Number of shared co-authors 11
Ian G Mills
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 20
Marshall Scott Lucia
University of Colorado School of Medicine
Career Start Year 1991
Number of shared co-authors 11
Teresa L Johnson-Pais
University of Texas Health San Antonio
Career Start Year 1990
Number of shared co-authors 5
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 14
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 8
Adrie van Bokhoven
University of Colorado Anschutz Medical Campus
Career Start Year 1988
Number of shared co-authors 3
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 45
Anders Bjartell
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 41
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 28
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1987
Number of shared co-authors 19
Fred C G J Sweep
Radboud University Medical Centre
Career Start Year 1987
Number of shared co-authors 0
Eric P Smith
University of Cincinnati College of Medicine
Career Start Year 1986
Number of shared co-authors 0
Dean A Troyer
Eastern Virginia Medical School
Career Start Year 1985
Number of shared co-authors 16
Stephen Fawell
Oncology R&D
Career Start Year 1984
Number of shared co-authors 0
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 0
Shalender Bhasin
Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1981
Number of shared co-authors 3
Gail P Risbridger
Biomedicine Discovery Institute, Monash University
Career Start Year 1981
Number of shared co-authors 20
Eleftherios P Diamandis
Lunenfeld-Tanenbaum Research Institute
Career Start Year 1981
Number of shared co-authors 4
David E Neal
University of Oxford, John Radcliffe Hospital
Career Start Year 1981
Number of shared co-authors 25
Christopher S Foster
The Institute of Cancer Research
Career Start Year 1978
Number of shared co-authors 14
Marc R Blackman
Washington DC VA Medical Center, Georgetown University, George Washington University
Career Start Year 1978
Number of shared co-authors 2
Simone Chevalier
McGill University Health Centre, McGill University
Career Start Year 1977
Number of shared co-authors 5
Ralph Buttyan
University of British Columbia
Career Start Year 1976
Number of shared co-authors 9
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 3
Gerhard A Coetzee
Van Andel Institute
Career Start Year 1972
Number of shared co-authors 9
John Trachtenberg
University of Toronto, University Health Network
Career Start Year 1971
Number of shared co-authors 7

Collaborators

Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 41
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 22
Elahe A Mostaghel
University of Washington
Co-authored papers 18
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 16
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 14
Sanjay Asthana
William S. Middleton Memorial Hospital
Co-authored papers 14
Robert L Vessella
University of Washington
Co-authored papers 12
Adam Sharp
The Institute for Cancer Research
Co-authored papers 11
Eva Corey
University of Washington School of Medicine
Co-authored papers 11
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 9
Colm Morrissey
Co-authored papers 9
Lawrence D True
University of Washington School of Medicine
Co-authored papers 9
Daniel W Lin
Co-authored papers 8
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 7
Alvin M Matsumoto
Co-authored papers 7
Susana Miranda
The Institute of Cancer Research
Co-authored papers 6
Wei Yuan
The Institute for Cancer Research
Co-authored papers 6
Itay Bentov
University of Washington
Co-authored papers 6
Suzanne Carreira
The Institute of Cancer Research
Co-authored papers 6
Gerard D Schellenberg
Co-authored papers 5
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 5
Michael C Haffner
Fred Hutchinson Cancer Center
Co-authored papers 5
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 5
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Co-authored papers 5
Martin E Gleave
University of British Columbia
Co-authored papers 5
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 4
Jonathan L Wright
University of Washington Medical Center
Co-authored papers 4
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 4
Luke A Selth
Adelaide Medical School, University of Adelaide
Co-authored papers 4
Rosina T Lis
National Cancer Institute
Co-authored papers 4
Release 1.2